CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total		Common Stock	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury stock
Beginning balance, shares at Dec. 31, 2022			77,770,588
Beginning balance at Dec. 31, 2022	$ 142,605		$ 776	$ 213,956	$ (66,112)	$ (33)	$ (5,982)
Net loss	(10,812)				(10,812)
Issuance of common stock, shares			4,312,500
Issuance of common stock	68,449		$ 43	68,406
Options exercised, shares			223,785
Options exercised	1,622		$ 2	1,620
Foreign currency translation	(99)					(99)
Employee stock purchase plan	122			122
Stock-based compensation	3,182			3,182
Ending balance, shares at Mar. 31, 2023			82,306,873
Ending balance at Mar. 31, 2023	205,069		$ 821	287,286	(76,924)	(132)	(5,982)
Beginning balance, shares at Dec. 31, 2023			82,825,455
Beginning balance at Dec. 31, 2023	169,725		$ 827	298,394	(123,646)	132	(5,982)
Net loss	(17,399)	[1],[2],[3]			(17,399)
Restricted stock vested, Shares			71,206
Restricted stock vested	$ (400)		$ 1	(401)
Options exercised, shares	48,750		48,750
Options exercised	$ 298			298
Foreign currency translation	(1,097)					(1,097)
Employee stock purchase plan	80			80
Stock-based compensation	3,088			3,088
Ending balance, shares at Mar. 31, 2024			82,945,411
Ending balance at Mar. 31, 2024	$ 154,295		$ 828	$ 301,459	$ (141,045)	$ (965)	$ (5,982)

[1] Trade Receivable Reserve - The correction of the misstatement resulted in an increase to Selling, general and administrative of $567 for the three-months ended March 31, 2024.

[2] Income Tax Adjustment - The correction of the misstatement resulted in a decrease to Income tax expense (benefit) of $58 for the three-months ended March 31, 2024.

[3] Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $1,656 for the three-months ended March 31, 2024.